Observational Study for Ductal Breast Carcinoma In Situ

The PREDICT Registry:

Recruiting Observational Study
DCIS Stage 0 Breast Cancer Ductal Breast Carcinoma In Situ
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
30 – 85
Sex
Female
Study type
Observational
Participants needed
3,000 (estimated)
Sponsor
PreludeDx · Industry
Who this trial is looking for

This trial is looking for women with ductal carcinoma in situ (DCIS) in one breast. Participants will be asked to give consent and may undergo a specific test as part of their routine care.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have ductal carcinoma in situ (DCIS) in one breast.
  • I am between 30 and 85 years old.
  • I have a tumor size of less than 6 cm.
  • I was diagnosed with DCIS within the last 120 days.
  • I can have breast-conserving surgery.
  • I can receive radiation or systemic treatment.
  • I have the DCISionRT test ordered during my care.

You may not be able to join if

  • I have invasive breast cancer or suspicious findings.
  • I have had a mastectomy for DCIS.
  • I have had any prior DCIS or invasive breast cancer.
  • I have had prior radiation in the same breast.
  • I have had systemic endocrine or chemotherapy before testing.
  • I am pregnant.
  • I do not have enough tissue for the test.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each pa…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria 1. Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable). 2. Patient must have the DCISionRT test ordered during routine patient…
Contacts

Steven C Shivers, PhD

813-215-1749

sshivers@preludedx.com

CONTACT

Leona Hamrick, DHSc

727-244-6411

lhamrick@preludedx.com

CONTACT